Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

Small Cell Lung Cancer Limited Stage Clinical Trial

Official title:

An Exploratory Clinical Study to Investigate Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04882033
• Other study ID #: ALTER-L039
• Status: Recruiting
• Phase: Phase 1
• Start date: May 7, 2021
• Est. completion date: July 1, 2023

Study information

• Verified date: May 2020
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Xiyan Nan, Doctor
• Phone: +86 18811796429
• Email: 18811796429[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the tolerability and toxicity of different dose of anlotinib combination with concurrent chemoradiotherapy in the treatment of limited-stage SCLC patients.

Description:

Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β c-Kit and MET. The purpose of this study is to determine the maximum tolerated dose of anlotinib when combination with concurrent chemoradiotherapy. From low dose group up to high dose group, each one had 3 patients at least. Primary group received anlotinib 8mg. The dose of anlotinib would increase gradually until MTD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: July 1, 2023
• Est. primary completion date: July 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients voluntarily participate in this study, signed informed consent.

2. Patients aged between 18 -75 years; According to the eighth edition of AJCC and the standard of the VALG two-stage staging method, the patient is confirmed by histology or cytology as limited-stage SCLC (stage I-III, any T, any N, M0) and cannot be operated on.

3. Patients with ECOG PS Scoring: 0~1 point

4. Patients with concurrent chemoradiotherapy must comply with relevant regulations.

5. PCI is given according to the judgment of the investigator.

6. Patients with normal organ function, the following criteria are met: (1) blood routine examination criteria (without blood transfusion in 14 days) : a) hemoglobin (HB) =90g/L; b) absolute neutrophil count (ANC) =1.5×10e9/L; c) platelet (PLT) =80×10e9/L; (2) biochemical tests meet the following criteria: a) total bilirubin (TBIL) =1.5 times of upper limit of normal (ULN); b) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 ULN, if liver metastasis occurred, ALT and AST =5 ULN; c) serum creatinine (Cr) =1.5 ULN or creatinine clearance (CCr) =60mL/min.

7. For women of child-bearing age, the pregnancy test results (serum or urine) within 1 week before enrolment must be negative. They will take appropriate methods for contraception during the study until the 6 months post the last administration of study drug. For men (previous surgical sterilization accepted), will take appropriate methods for contraception during the study until the 6 months post the last administration of study drug.

Exclusion Criteria:

1. Small cell and non-small cell mixed lung cancer

2. Extensive stage small cell lung cancer

3. Central lung tumors that imaging shows tumor lesions invade local large blood vessels; or with significant pulmonary cavum or necrotizing

4. Less than 4 weeks from the last clinical trial or participating in other clinical studies.

5. History:

1) Brain metastasis or spinal cord compression 2) Other active malignancies that require simultaneous treatment. 3) History of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease, or history of organ transplantation.

4) History of mental drug abuse and cannot be cured or have mental disorders 6. Patients with any severe and/or uncontrolled disease, including:

1. blood pressure control is not ideal (systolic blood pressure = 150 mmHg, diastolic blood pressure = 100 mmHg);

2. Significant cardiac disease as defined as: grade I or greater myocardial infarction, unstable arrhythmia (including corrected QT interval (QTc ) period between male or greater 450 ms, female or greater 470 ms); New York Heart Association (NYHA) grade II or greater heart dysfunction , or Echocardiography reveal left ventricular ejection fraction (LVEF) less than 50%

3. Decompensated diabetes or other remedies for high-dose glucocorticoid therapy.

4. Exacerbation of chronic obstructive pulmonary disease (COPD) or other serious respiratory diseases that require hospitalization

5. Active or uncontrollable serious infection (=CTC AE Level 2 infection);

6. Uncontrolled pleural effusion, pericardial effusion and abdominal effusion requiring repeated drainage.

7. Urine routine test protein=++, and confirmed 24 hours urine protein>1.0 g; 7. Imaging shows that the tumor has been violated around important vascular or the researchers determine the tumor is likely to invade important blood vessels caused by fatal bleeding during the follow-up.

8. Patients who received a major surgical treatment or severe trauma, the effects of surgery or trauma have been eliminated in less than 2 weeks before being enrolled 9. Patients with clinically significant hemoptysis occurred within 3 months prior to enrollment (greater than 1/2 teaspoon of bright red blood). History of clinically relevant major bleeding event (e.g. gastrointestinal hemorrhage, hemorrhagic acne, bleeding gastric ulcer, occult blood test = ++, or vasculitis, etc.) 10. Patients who have arterial/venous thromboembolism events within 6 months before being enrolled, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.

11. Coagulation disfunction(INR>1.5 or PT>upper limit of normal(ULN)+4s or activated partial thromboplastin time (APTT) >1.5 upper limit of normal (ULN)), hemorrhagic tendency or receiving the therapy of thrombolysis or anticoagulation.

12. At the discretion of the investigator, the patient may have other factors that may cause the study to be terminated midway.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer Limited Stage
• Small Cell Lung Carcinoma

Intervention

Drug:
• Concurrent chemoradiotherapy plus anlotinib
Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects). Chemotherapy: For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w. Radiotherapy: For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60~66Gy.

Locations

Country	Name	City	State
China	Tianjin Medical University Cancer Institute and Hospital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerance Dose (MTD) is the dose of treatment in the cohort where there are 2 cases of DLT reported.	Dose Limiting Toxicity (DLT) is referred to grade 3 non-hematological toxicity or grade 4 hematological toxicity according to NCI CTCAE 4.03 criteria	From enrollment to completion of study. Estimated about 18months
Secondary	PFS(Progress free survival)	The PFS time is defined as time from enrollment to locoregional or systemic	each 42 days up to intolerance the toxicity or PD (up to 24 months)
Secondary	OS(Overall Survival)	OS was defined as time from date of enrollment to date of death due to any cause.	From enrollment until death (up to 24 months)
Secondary	ORR(Objective Response Rate)	Objective Response Rate (ORR) is defined as participants who had complete response (CR) or partial response(PR) divided by the total number of patients.	each 42 days up to intolerance the toxicity or PD (up to 24 months)
Secondary	DCR(Disease Control Rate)	Disease Control Rate (DCR) defined as the percentage of participants with Disease Control best overall response (complete response, partial response or stable disease).	each 42 days up to intolerance the toxicity or PD (up to 24 months)